Jump to content
Sign in to follow this  
Dr. Okun

New Study: A New Target for the Treatment of Dyskinesia

Recommended Posts

This researcher from NYU has been working on a new potential drug target for the treatment of Dyskinesia


Sci Signal. 2009 Jul 21;2(80):pe42. Links

Thwarting dyskinesia by targeting mTORC1.


Klann E.

Center for Neural Science, New York University, New York, NY 10003, USA. eklann@cns.nyu.edu

In a mouse model of Parkinson's disease, new evidence shows that l-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1) prevents the development of dyskinesia, but not the antiakinetic benefits produced by l-DOPA. Thus, mTORC1 may be a viable therapeutic target for dyskinesia caused by l-DOPA treatment in patients with Parkinson's disease.

Share this post

Link to post
Share on other sites
Sign in to follow this